On Feb. 1, the Roche Group reported its 2018 annual earnings of 568.4.6 billion Swiss francs.Compared to 532 in 2017.9. 9 billion Swiss francs up 7%.Of which pharmaceutical business 439.6.7 billion Swiss francs, 128.7.9 billion Swiss francs.Pharmaceutical business growth was driven largely by the drugs Ocrevus, Perjeta, Tecentriq, Alecensa and Hemlibra, according to the report.
Roche is the benchmark of Her2 + breast cancer drug market, continuously raising the clinical treatment standard and competitive threshold, and the total market share of breast cancer drug troika also continuously hit a new high.On December 17, 2018, the marketing application of Perjeta in China was approved by China Food and Drug Administration for the adjuvant treatment of patients with human epidermal growth factor receptor 2 (HER2) -positive early breast cancer at high risk of recurrence (see: Roche Perjeta approved!The clinical gold standard trastuzumab + pertuzumab opens a new era of breast cancer treatment in China).However, Herceptin's revenue in Europe fell 16 percent because of the availability of biosimilars.With Herceptin growth stagnating, Perjeta has emerged as Roche's new Her2 + king with steadily high growth.
Roche Her2 + Breast Cancer Drug Sales (million Swiss francs)On the plus side, Gazyva, an upgraded rituximab product, is up 40% in 2018.Just a few days ago, Gazyva + Ibrutinib was approved for the first-line treatment of CLL/SLL, and the performance growth rate is expected to be further improved.
Roche pharmaceutical sales in 2018 (100 million Swiss francs)
Ocrevus（ocrelizumab）Approved by the FDA for the treatment of multiple sclerosis in 2017/3/28, it is not only the longest-lasting MS treatment (1 injection in 6 months), but also the first drug approved to treat two types of MS. (See: 2017 FDA approved new drugs), sales revenue surged 172% in 2018, reaching an amazing23.53 billion Swiss francs, while becoming a Roche TOP5 drug, also contributed to partner Bioge 4.The $7.8 billion coalition is divided into revenues.Ocrevus is a new benchmark in the field, compared with Biogen's sluggish multiple sclerosis business.
Another outstanding product of Roche is Alecensa for ALK positive NSCLC. Although it is marketed later than Pfizer and Novartis like products, Alecensa's revenue in 2018 is up to 6.3.7 billion Swiss francs, an absolute lead (see: Heavy!Alectinib is approved for first-line use and will become the new king of ALK + lung cancer market.
In 2018, Roche has also made great achievements in the approval of new drugs.Just last December, the FDA approved the PD-L1 tumor immunotherapy Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) and chemotherapy (paclitaxel + carboplatin) for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSq NSCLC) without EGFR or ALK genomic tumor aberrations.Tecentriq sales rose 59% to 7. 5% in 2018.7.2 billion Swiss francs.
In addition, the FDA has accelerated approval of venetoclax in combination with demethylating agents (azacitidine or decitabine), or low-dose cytarabine (LDAC) chemotherapy, for newly diagnosed patients over 75 years of age.Or AML patients who cannot use high-intensity chemotherapy due to chronic health problems and diseases.
On October 25, 2018, the FDA approved a single oral dose of XOFLUZA (baloxavir marboxil) for the treatment of acute, uncomplicated or influenza in people 12 years of age and older.
The FDA has approved a priority review of the Supplemental Biologics License Application (sBLA) for Tecentriq (atezolizumab) in combination with carboplatin and etoposide for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC) based on the IMpower 133 study.The FDA also granted the application a priority review status and is expected to make a decision on approval by March 18, 2019.